Overview
VVOS market data
Price History
VVOS price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.06 Diluted earnings per share over the trailing twelve months.
- Beta
- 6.23 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.36 – $5.69 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $5.7 · P/B 3.18 · P/S 0.29.
Company News
8-K filing — Vivos Therapeutics, Inc. (VVOS)SEC EDGAR · Jul 7, 2026, 9:29 PM
Vivos Therapeutics Announces Its Treatment With ITS FDA-Cleared Vida Oral Appliance Demonstrates Enhancement In Insomnia Severity In 100% Of Patients In TrialBenzinga · Jun 30, 2026, 12:50 PM
Vivos Extends Streeterville Financing Deal Through Aug. 31, Reaffirms Plan To Convert Up To $4.5M Debt Into Preferred And Common StockBenzinga · Jun 22, 2026, 12:45 PM
Streeterville Extends Strategic Financing Deal With Streeterville Through August 31, Reaffirming Plan To Convert Up To $4.5M Debt Into Preferred And Common StockBenzinga · Jun 22, 2026, 12:40 PM
Vivos Therapeutics Announces Intent To File Registration For Proposed Rights OfferingBenzinga · Jun 11, 2026, 12:36 PM
Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026Globenewswire Inc · Jun 8, 2026, 6:15 PM
Vivos Therapeutics Enters Senior Debt-to-Equity Exchange Agreement With Streeterville Capital For Up To $4.5MBenzinga · Jun 5, 2026, 12:50 PM
CrowdStrike To Surge Nearly 25%? Here Are 10 Notable Analyst Calls From ThursdayBenzinga · Jun 4, 2026, 12:45 PM
Vivos Therapeutics Q1 EPS $(0.52) Misses $(0.45) Estimate, Sales $5.141M Beat $4.225M EstimateBenzinga · May 20, 2026, 8:25 PM